No Need for Triple Therapy or Second Transplant for Multiple Myeloma
نویسندگان
چکیده
منابع مشابه
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
BACKGROUND Elotuzumab, an immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7), showed activity in combination with lenalidomide and dexamethasone in a phase 1b-2 study in patients with relapsed or refractory multiple myeloma. METHODS In this phase 3 study, we randomly assigned patients to receive either elotuzumab plus lenalidomide and dexamet...
متن کاملNo role for triple antiplatelet therapy?
Studies have shown that adjunctive cilostazol to dual ntiplatelet therapy in patients undergoing percutaneous oronary intervention (PCI) may decrease late restenosis nd enhance inhibition of adenosine diphosphate (ADP)nduced platelet aggregation, providing a rationale for triple ntiplatelet therapy (3–5). The appealing hypothesis that riple antiplatelet therapy may provide more profound latelet...
متن کاملPost-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma
Autologous stem cell transplant (ASCT) is the standard of care in transplant-eligible multiple myeloma patients and is associated with significant improvement in progression-free survival (PFS), complete remission rates (CR), and overall survival (OS). However, majority of patients eventually relapse, with a median PFS of around 36 months. Relapses are harder to treat and prognosis declines wit...
متن کاملMultiple myeloma and renal transplant.
Until now, no case of multiple myeloma (MM) had been reported among the B-lymphoproliferative disorders occurring in organ-transplant recipients. The history of a 58-year-old man who developed IgG-kappa MM 31 months after a cadaveric renal transplant is described. A possible relationship between drug-mediated immunosuppression and the development of MM is discussed.
متن کاملSecond Primary Malignancies and Myeloma Therapy: Fad or Fact?
The risk adaptive therapy approach within low risk patients may involve limiting post-transplant IMiD exposure in patients who have a higher potential for SPM development. It may well be that we are looking at the tip of the iceberg in the year 2012 and SPMs may emerge as an important long-term sequela with further follow-up.
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Oncology Times
سال: 2017
ISSN: 0276-2234
DOI: 10.1097/01.cot.0000513048.92804.7c